FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      
           
This page is updated frequently with new Mammal-related patent applications. Subscribe to the Mammal RSS feed to automatically get the update: related Mammal RSS feeds. RSS updates for this page: Mammal RSS RSS


Date/App# patent app List of recent Mammal-related patents
04/23/15
20150113669
 Animal models and therapeutic molecules patent thumbnailnew patent Animal models and therapeutic molecules
The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited
04/23/15
20150111947
 Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage patent thumbnailnew patent Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage
Provided herein are methods of decreasing leukocyte extravasation from a lymph or blood vessel into a tissue in a mammal, methods of decreasing fluid leakage from a lymph or blood vessel in a mammal in need thereof, methods of decreasing formation of atherosclerotic plaques in a mammal in need thereof, and methods of treating atherosclerosis in a mammal that include administering to the mammal an oligonucleotide that decreases mitogen-activated protein kinase kinase kinase kinase 4 (map4k4) mrna expression in an endothelial cell. Also provided are methods of identifying a candidate agent useful for decreasing leukocyte extravasation or decreasing fluid leakage from a lymph or blood vessel in a mammal, and compositions containing an oligonucleotide that decreases map4k4 mrna expression in an endothelial cell and additional therapeutic agents..
University Of Massachusetts
04/23/15
20150111945
 Compositions and methods for silencing ebola virus gene expression patent thumbnailnew patent Compositions and methods for silencing ebola virus gene expression
The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering rna such as sirna) that target ebola virus (ebov) gene expression and methods of using such compositions to silence ebov gene expression. More particularly, the invention provides unmodified and chemically modified interfering rna which silence ebov gene expression and methods of use thereof, e.g., for preventing or treating ebov infections caused by one or more ebov species such as zaire ebov.
United States Army Medical Research And Materiel Command
04/23/15
20150111891
 Naphthalene acetic acid derivatives against hiv infection patent thumbnailnew patent Naphthalene acetic acid derivatives against hiv infection
The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an hiv infection, treating the proliferation of the hiv virus, treating aids or delaying the onset of aids or arc symptoms in a mammal using compounds disclosed herein..
Gilead Sciences, Inc.
04/23/15
20150111870
 Quinolinyl modulators of roryt patent thumbnailnew patent Quinolinyl modulators of roryt
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/23/15
20150111825
 Osteocalcin as a treatment for male reproductive disorders patent thumbnailnew patent Osteocalcin as a treatment for male reproductive disorders
Methods and compositions for treating, preventing, or diagnosing disorders related to reproduction in male mammals, preferably humans, are provided. The methods generally involve modulation of the ost-ptp signaling pathway or the ptp-1b signaling pathway involving gamma-carboxylase and osteocalcin.
The Trustees Of Columbia University In The City Of New York
04/23/15
20150111821
 Mutated fibroblast growth factor (fgf) 1 and methods of use patent thumbnailnew patent Mutated fibroblast growth factor (fgf) 1 and methods of use
The present disclosure provides fgf1 mutant proteins, such as those having an n-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant fgf1 proteins can be part of a chimeric protein that includes a β-klotho-binding protein, an fgfr1c-binding protein, a β-klotho-binding protein and a fgfr1c-binding protein, a c-terminal region from fgf19 or fgf21.
Salk Institute For Biological Studies
04/23/15
20150111814
 Novel compositions for promoting hiv-1 virolysis and methods using same patent thumbnailnew patent Novel compositions for promoting hiv-1 virolysis and methods using same
The present invention includes compounds that are useful for treating or preventing a hiv-1 infection in a mammal. In certain embodiments, the compounds cause cell-free virolysis of an hiv-1 virus.
Drexel University
04/23/15
20150111771
 Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method patent thumbnailnew patent Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method
The present invention relates to an in vitro method for identifying agents capable of inducing respiratory sensitization in a mammal and arrays and diagnostic kits for use in such methods. In particular, the methods include measurement of the expression of the biomarkers listed in table 1a, table 1b and/or table 1c in mutz-3 cells exposed to a test agent..
Senzagen Ab
04/23/15
20150111232
 Soluble b7-h1 patent thumbnailnew patent Soluble b7-h1
This document features methods of evaluating mammals by assessing expression of b7-h1 in a body fluid.. .
Mayo Foundation For Medical Education And Research
04/23/15
20150111193
new patent

Methods and solutions for tissue preservation


Described herein are compositions and methods particularly useful in the medical arts. The compositions and methods may be used in connection with the preservation of a portion of a mammal, for example, tissues, organs, appendages, limbs, extremities, stem cells, myocytes, bone marrow, skeletal muscle as well as an array of other medical procedures, such as cardiac surgery, transplantation and/or preservation.
Cedars-sinai Medical Center
04/23/15
20150110906
new patent

Herbal composition phy906 and its use in chemotherapy


This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy.
Yale University
04/23/15
20150110862
new patent

Sweet gum fruit extract as a therapeutic agent


Sweet gum (liquidambar styraciflua l., family hamamelidaceae) fruit extract was discovered to possess potent activities against multiple targets of the pi3k (phosphatidylinositide 3-kinase) pathway, especially the pi3k/akt and mtor pathways. At a very low concentration of 1.85 μg/ml (ic50), sweet gun extract showed the ability of simultaneously blocking the pathways of pi3k/akt (upstream), mtor (mammalian target of rapamycin) (downstream), as well as its downstream protein products s6k and s6.
Board Of Regents
04/23/15
20150110839
new patent

High-loading, controlled-release magnesium oral dosage forms and methods for making and using same


Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components.
Pharmalyte Solutions, Llc
04/23/15
20150110838
new patent

Compositions and methods for treating crohn's disease and related conditions and infections


In alternative embodiments, the invention provides a “triple combination” therapy for treating, ameliorating and preventing crohn's disease (or crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes crohn's disease or paratuberculosis infection in mammals.
04/23/15
20150110823
new patent

Particulate vaccine formulations


The present disclosure provides vaccine formulations comprising at least one peptide antigen assembly and at least one adjuvant. The disclosure also provides methods of inducing an immune response in a mammal and methods of treating a disease in a mammal utilizing the vaccine formulations..
Pds Biotechnology Corporation
04/23/15
20150110755
new patent

Elastin producing fibroblast formulations and methods of using the same


The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides.
The Hospital For Sick Children
04/23/15
20150110748
new patent

Bone grafts including osteogenic stem cells, and methods relating to the same


Bone grafts and constructs including stem cells are provided. Example bone grafts include osteogenic stem cells seeded on a scaffold of osteoconductive cortico-cancellous chips and/or osteoinductive demineralized bone.
Globus Medical, Inc.
04/23/15
20150110747
new patent

Bone grafts including osteogenic stem cells, and methods relating to the same


Bone grafts and constructs including stem cells are provided. Example bone grafts include osteogenic stem cells seeded on a scaffold of osteoconductive cortico-cancellous chips and/or osteoinductive demineralized bone.
04/23/15
20150110737
new patent

Methods of producing and using regulatory b-cells


The invention is directed to a method of preparing b-cells that produce interleukin-10 (il-10), or il-10 per se, which comprises contacting one or more b-cells ex vivo with an isolated interleukin-35 (il-35) protein, and culturing the one or more b-cells under conditions to provide one or more b-cells that produce il-10. The invention also is directed to a method of suppressing the proliferation of lymphocytes in vitro or in vivo by contacting lymphocytes with an isolated il-35 protein.
The United States Of America, As Represented By Secretary, Department Of Health And Human Services
04/23/15
20150110724
new patent

High spf transparent or translucent naturally derived, cytoprotective, uv radiation resistant compositions


A composition comprising (a) at least one inorganic sun-block or sunscreen agent that is a proven non-endocrine disrupter, (b) at least one emollient or mixtures thereof proven to be a non-endocrine disrupter; (c) at least one emulsifier; and (d) an oil component capable of boosting spf values. The compositions of the present invention are shown to be capable of protecting skin and mammalian health from the harmful effects of radiation including ultraviolet light or sunlight by inhibiting the loss of skin immuno-competency and eliminating any known or suspected endocrine disrupting agents normally utilized as sun protective agents.
04/16/15
20150105638

Photoplethysmography device and method


A system and method for measuring one or more light-absorption related blood analyte concentration parameters of a mammalian subject, is disclosed. In some embodiments, the system comprises: a) a photoplethysmography (ppg) device configured to effect a ppg measurement by illuminating skin of the subject with at least two distinct wavelengths of light and determining relative absorbance at each of the wavelengths; b) a dynamic light scattering measurement (dls) device configured to effect a dls measurement of the subject to rheologically measure a pulse parameter of the subject; and c) electronic circuitry configured to: i) temporally correlating the results of the ppg and dls measurements; and ii) accordance with the temporal correlation between the ppg and dls measurements, assessing value(s) of the one or more light-absorption related blood analyte concentration parameter(s)..
Oxitone Medical Ltd.
04/16/15
20150105414

Hair growth and/or regrowth compositions


The present disclosure relates to compositions containing certain pyrimidine compounds such as minoxidil and/or certain pyrimidine sulfate (inner salt) compounds such as minoxidil sulfate and especially compositions containing pyrimidine compounds in combination with an admixtures comprising at least one antioxidant, at least one organic acid and a select fatty acid mixture. The present disclosure also relates to use of the compositions to grow and/or regrow hair and/or prevent hair loss in mammals and particularly in humans..
Mcneil-ppc, Inc.
04/16/15
20150105404

Phenyl linked quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/16/15
20150105381

Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors


The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (i), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.. .
Domain Therapeutics
04/16/15
20150105372

Secondary alcohol quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/16/15
20150105369

Alkyl linked quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/16/15
20150105366

Methylene linked quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/16/15
20150105365

Heteroaryl linked quinolinyl modulators of rorgammat


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/16/15
20150105363

Methods and formulations for treating scars and beta-catenin-mediated disorders


A topical drug composition for treating a β-catenin-mediated disorder in a mammal is provided comprising a nefopam compound selected from nefopam, or a functionally equivalent analogue, prodrug, salt or solvate thereof.. .
04/16/15
20150105361

Methods for treating polycystic kidney disease and polycystic liver disease


The present invention provides compounds of formula (i) or (ii), which are thought to be able to inhibit mtor (mammalian target of rapamycin) signaling pathway, induce upr (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (pkd, e.g., autosomal dominant pkd (adpkd) or autosomal recessive pkd (arpkd)) or polycystic liver disease (pld, e.g., autosomal dominant pld (adpld) or autosomal recessive pld (arpld)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating pkd or pld, inhibiting the growth of a cyst cell, and/or killing a cyst cell..
Yale University
04/16/15
20150105274

Methods for the characterisation of interaction sites on target proteins


The present invention relates to improved and integrated methods for the characterisation of an interaction site on a target protein that modulates the phenotype of a mammalian cell, such as a phenotype other than death and/or reduced growth. Such methods of the present invention include those to identify a target protein modulates such a phenotype of a mammalian cell, and optionally to characterise an interaction site on said target protein.
Cambridge Enterprise Limited
04/16/15
20150104820

Method for production of eosinophil from pluripotent stem cell


The present invention relates to a method for producing human eosinophils from human pluripotent stem cells. More specifically, the present invention provides a method for producing human eosinophils from human pluripotent stem cells, which method comprises the steps of: (1) co-culturing, in the presence of vegf, human pluripotent stem cells with cells separated from the agm region of a mammalian fetus; (2) performing suspension culture using a medium comprising il-3, il-6, flt3 ligand, scf, tpo and serum; (3) performing suspension culture using a medium comprising il-3, scf, gm-csf and serum; and, optionally, (4) performing suspension culture using a medium comprising il-3, il-5 and serum..
Kyoto University
04/16/15
20150104489

Therapeutic for treating clostridium difficile infection


The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing c. Difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing c.
London School Of Hygiene And Tropical Medicine
04/16/15
20150104479

Meningococcus serogroup x conjugate


The invention provides a conjugate of a neisseria meningitidis serogroup x capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate.
Novartis Ag
04/16/15
20150104477

Ubiquitinylated proteins


A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture.
04/16/15
20150104434

Artificial kidney precursor and process for production thereof


The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof.. .
Tokyo Women's Medical University
04/16/15
20150102925

Systems and methods for detection of biological conditions in humans


A method detects a biological condition and detects a change in the biological condition of a mammal. The device determines if the change in the biological condition exceeds a predetermined threshold and sends a signal based at least in part on the determination..
Aegis Industries, Inc.
04/09/15
20150100251

Systems and methods for sensing balanced-action for improving mammal work-track efficiency


An example system includes one or more sleeves, each configured for attachment to a leg and comprising a pressure sensor, an accelerometer and a magnetometer. A processor processes sensor signals from the pressure sensor, the accelerometer and the magnetometer to estimate action (a) and work (w) using event detections of peak stance and valley swing events associated with leg movement, for optimizing energy efficiency for maintaining a balance of the body leaning forward in a gravity pull-down force, with the periodic upward force of the sequential foot-thrusts with the toes..
04/09/15
20150100072

Length of self-retaining suture and for using the same


A method and device for anchoring a length of self-retaining suture. The method of anchoring includes providing for an assembly having a length of self-retaining suture and a suture insertion device.
Ethicon, Inc.
04/09/15
20150099874

Cytotoxic benzodiazepine derivatives


The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (i)-(vii). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent.
Immunogen, Inc.
04/09/15
20150099802

Selective tumor treatment


A method for treating a tumor with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-pgdh) in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative, a method for suppressing the growth of a tumor cell with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-pgdh), which comprises contacting said tumor cell with an effective amount of a fatty acid derivative, and a method for identifying a subject who would be responsive to a fatty acid derivative, comprising, (i) obtaining a biological sample from said subject; and (ii) measuring 15-hydroxyprostaglandin dehydrogenase (15-pgdh) level are provided.. .
Sucampo Ag
04/09/15
20150099787

Non-flushing niacin analogues, and methods of use thereof


One aspect of the present invention relates to substituted pyridines and pharmaceutially acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College
04/09/15
20150099782

Antagonists of prostaglandin ep3 receptor


Provided herein are antagonists of prostaglandin ep3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.. .
Pfizer Inc.
04/09/15
20150099781

Compounds and methods for treating mammalian gastrointestinal microbial infections


Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of impdh. In certain embodiments, a compound of the invention selectively inhibits a parasitic impdh versus a host impdh.
The Brigham And Women's Hospital, Inc.
04/09/15
20150099758

Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof


The present application is related to compounds represented by formula i, which are novel positive allosteric modulators of al nachrs. The application also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on al nachrs in a mammal by administering an effective amount of a compound of formula i..
Anvyl Llc
04/09/15
20150099727

Aminosteroids for the treatment of a ptp1b associated disease


This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme ptp1b in a mammal for the treatment of diabetes.. .
Ohr Pharmaceutical Inc.
04/09/15
20150099713

Method of treating constipation-predominant irritable bowel syndrome


Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufactiurc of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora.
Cedars-sinai Medical Center
04/09/15
20150099707

Modified pseudomonas exotoxin a


The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more b-cell and/or t-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions.
Hoffmann-la Roche Inc.
04/09/15
20150099668

Metabolite biomarkers for staging colorectal cancer


This document provides methods and materials for assessing metabolites in a sample from a mammal (e.g., human) for determining the nature and extent of colorectal cancer (crc) metastasis. For example, the document relates to the diagnosis, staging and prognosis of crc in a mammal..
Uti Limited Partnership
04/09/15
20150099032

Nutritional compositions and methods


Nutritional compositions comprising a botanical component, such as adaptogenic botanical component, comprising one or more ginsenosides and an amino acid component. Botanical components include ginsenosides, such as a panax extract (e.g., a panax notoginseng extract), an astragalus extract (e.g., an astragalus membranaceus extract), a rosa extract (e.g., a rosa roxburghii extract), fractions thereof, active components thereof, and combinations thereof.
Vitathlete, Vitaman Llc
04/09/15
20150099022

Phytoecdysones for use in improving the muscle quality of obese and/or sarcopenic mammals


Phytoecdysones for use in improving muscle quality in obese and/or sarcopenic mammals, preferably, obese mammals subjected to a low-calorie diet. The phytoecdysones are advantageously incorporated into a food composition.
Institut National De La Recherche Agronomique
04/09/15
20150099021

Medicinal composition of extract of seed of emblica officinalis and preparing the same


A composition having an extract of seed of emblica officinalis. Methods of preparing extract of seed of emblica officinalis.
04/09/15
20150098946

Compositions and methods for the diagnosis and treatment of tumor


The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a dna molecule encoding a full-length tat polypeptide having an amino acid sequence as disclosed herein, a tat polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane tat polypeptide, with or without the signal peptide, as disclosed herein..
Genentech, Inc.
04/09/15
20150098897

Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma


Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (ifn-gamma) or an agent that increases the expression of ifn-gamma in the subject.
Engenelc Molecular Delivery Pty Ltd
04/02/15
20150096063

Mouse artificial chromosome vector


Disclosed is a mouse artificial chromosome vector, comprising: a natural centromere derived from a mouse chromosome; a mouse-chromosome-derived long-arm fragment formed by deleting a long-arm distal region at a mouse chromosome long-arm site proximal to the centromere; and a telomere sequence, wherein the vector is stably retained in a cell and/or tissue of a mammal. In addition, disclosed are cells or non-human animals comprising the vector, and use of the cells or non-human animals..
Chromocenter Inc.
04/02/15
20150094376

Hexamethonium reverses the lethal cardiopulmonary damages in a rat model of brain stem lesions mimicking fatal enterovirus 71 encephalitis


Disclosed is a method for inhibiting the excessive release of catecholamines of mammals infected by the enterovirus 71 (ev71), and more specially, a method for reversing the cardiopulmonary damages caused from ev71 infection in an animal model by using hexamethoniums. An early administration of a suitable amount of hexamethonium to the rats mimicking enterovirus 71 infection will attenuate the acute excessive release of catecholamines in the body of each rat.
Kaohsiung Veterans General Hospital
04/02/15
20150094347

Benzoxepin pi3k inhibitor compounds and methods of use


Benzoxepin compounds of formula i, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: z1 is cr1 or n; z2 is cr2 or n; z3 is cr3 or n; z4 is cr4 or n; and where (i) x1 is n and x2 is s, (ii) x1 is s and x2 is n, (iii) x1 is cr7 and x2 is s, (iv) x1 is s and x2 is cr7; (v) x1 is nr8 and x2 is n, (vi) x1 is n and x2 is nr8, (vii) x1 is cr7 and x2 is o, (viii) x1 is o and x2 is cr7, (ix) x1 is cr7 and x2 is c(r7)2, (x) x1 is c(r7)2 and x2 is cr7; (xi) x1 is n and x2 is o, or (xii) x1 is o and x2 is n, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of pi3k, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
Genentech, Inc.
04/02/15
20150094323

Methods of treating and/or preventing cardiovascular disease


Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are provided.. .
Murray And Poole Enterprises Limited
04/02/15
20150094322

Sustained-release formulations of colchicine and methods of using same


Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile.
Murray And Poole Enterprises Limited
04/02/15
20150094307

Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof


Amino, amido, and heterocyclic compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to rage activity..
04/02/15
20150094303

Niacin mimetics, and methods of use thereof


Disclosed are heterocyclylalkyl-substituted and heteroaralkyl-substituted pyridines, and pharmaceutically acceptable salts and prodrugs thereof, that are active against a range of mammalian therapeutic indications.. .
Arisaph Pharmaceuticals, Inc.
04/02/15
20150094302

Alkylated piperazine compounds


Alkylated piperazine compounds of formula i are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting btk kinase, and for treating cancer mediated by btk kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, and treatment of cancer in mammalian cells, or associated pathological conditions, are disclosed..
Genentech, Inc.
04/02/15
20150094294

Compounds and methods for treating malaria


The present disclosure provides compounds, specifically pyrimidin-4,6-dicarboxylic acid amide derivatives, or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing said compounds. Also provided are methods for treating a mammal having malaria, or killing or inhibiting the growth of a plasmodium species, comprising administering to said mammal or contacting said plasmodium species with, an effective amount of a pyrimidin-4,6-dicarboxylic acid amide derivative..
The Trustees Of The University Of Pennsylvania
04/02/15
20150094268

Prophylactic or therapeutic agent for hepatic diseases


The present invention provides a prophylactic or therapeutic agent for a hepatic disease, containing aim or a partial peptide thereof, or a nucleic acid containing a base sequence encoding the same, a method of screening for a prophylactic or therapeutic agent for a hepatic disease, comprising using an0 animal obtained by loading a non-human mammal deficient in aim expression with a high fat diet and the like.. .
04/02/15
20150094260

Buffered ophthalmic compositions and methods of use thereof


The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the buffer provides increased mechanism of action of pharmaceutically active agents as well as therapeutic qualities.
Arava Bio-tech Ltd.
04/02/15
20150094236

Nucleotides for prevention and treatment of bacterial and fungal pathologies


A selectively inducible, single-stranded dna (ssdna) expression library, a method for constructing a ssdna expression library, a method for screening ssdna using the expression library, and a method for identifying ssdna molecules that alter expression of bacterial and fungal gene(s) related to cell growth and toxin production and secretion. The screening library is used to, among other things, identify odns effective in stopping cell growth, killing bacteria or fungi, or preventing bacteria and/or fungi from synthesizing and secreting their toxins, and/or to discover odns effective in eukaryotic (e.g., mammalian) cells for targeted alteration of gene function.
Star Biologics, Inc.
04/02/15
20150094230

Method and system for detecting and differentiating cancer and sepsis in mammals using biomarkers


The invention provides a method and system for developing and using diagnoses of cancer and sepsis in canine subjects using thymidine kinase (tk), c-reactive protein (crp), and c-type natriuretic peptide (cnp) as biomarkers. The level of each biomarker may be measured and an index may be computed using a two- or a three-biomarker method.
Veterinary Diagnostics Institute, Inc.
04/02/15
20150093824

Methods and compositions for inhibiting the function of polynucleotide sequences


A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded rna molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This rna molecule desirably does not produce a functional protein.
Alnylam Pharmaceuticals, Inc.
04/02/15
20150093784

Cell culture improvements


The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture..
Abbvie Inc.
04/02/15
20150093781

Microorganism for expressing a human membrane protein


The invention relates to an isolated, genetically modified, living non-mammal organism, having increased hmg-coa-reductase activity compared to the wild type, and having reduced c24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type.
Organobalance Gmbh
04/02/15
20150093746

Virus causing respiratory tract illness in susceptible mammals


The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded rna virus (mpv) within the subfamily pneumovirinae of the family paramyxoviridae and identifiable as phylogenetically corresponding to the genus metapneumovirus and components thereof..
Vironovative Bv
04/02/15
20150093717

Devices and methods for enhancing bone growth


The present invention is generally related to implants for compensating bone loss in mammalian body, and to devices and methods for replacing or creating facial bone. The present invention relates to devices and methods for implanting an implantable device in a subject's body.
04/02/15
20150093445

Formulations and methods for treatment of acne and inflammatory skin conditions


Topically administrable compositions and methods for treating skin conditions in mammals, such as acne, rosacea, keratosis pilaris, photo-aging, and photo-rejuvenation. The composition includes a therapeutic amount of antihistamine selected from the group consisting of a non-sedating antihistamine, a physiologically acceptable acid of a non-sedating antihistamine, a salt of a non-sedating antihistamine, an amide of a non-sedating antihistamine, and a combination of two or more of these, and emu oil product selected from the group consisting of emu oil, a biologically active fraction of emu oil, and a combination of these.
Zemtsov Enterprises, Llc
04/02/15
20150093412

Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax


Provided are immunogenic compositions and methods for eliciting an immune response against b. Anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides.
National Research Council Of Canada
04/02/15
20150093400

Peptides for management of lactation


The present invention provides novel short peptides that are highly effective in inducing involution in a mammary gland of a lactating mammal and cessation of milk production by the gland. The invention further provides pharmaceutical composition comprising the peptides and methods of use thereof including for treating microbial infection in a mammary gland..
Mileutis Ltd.
04/02/15
20150093395

Anti-fxi antibodies and methods of use


Disclosed herein are monoclonal antibodies specific for factor xi (fxi) that prevent activation of fxi by factor xiia (fxiia). The monoclonal antibodies are universal fxi antibodies, capable of binding all mammalian species tested.
Oregon Health & Science University
04/02/15
20150093369

Mixture of enzymes from antarctic krill for use in the removal of a biofilm


The invention concerns a mixture of enzymes from krill for use in the treatment of a soft tissue including epithelial tissue and mucosa on which soft tissue a biofilm has formed or is expected to form, which soft tissue is a soft tissue of a mammal and which treatment comprises the removal of the biofilm or preventing a formation of the biofilm.. .
Arcimboldo Ab
04/02/15
20150093365

Photoactivatable caged tamoxifen and tamoxifen derivative molecules and methods of use thereof


Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source.
Dana-farber Cancer Institute, Inc.
04/02/15
20150093356

Thrombopoietin mimetics


Invented are non-peptide tpo mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds.
Glaxosmithkline Llc


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         















0.7034

3357

1 - 1 - 80